Equities Analysts Set Expectations for SPRY FY2025 Earnings

Key Points

• Analysts at Cantor Fitzgerald lowered ARS Pharmaceuticals' FY2025 earnings per share estimate from ($1.44) to ($1.92), while the consensus estimate for the current full-year earnings is ($0.55) per share.
• Wall Street Zen downgraded the stock's rating from "hold" to "sell", with an average target price of $31.00 and mixed ratings from various analysts.
• ARS Pharmaceuticals' latest quarterly earnings missed estimates by ($0.05), reporting ($0.46) per share, while revenues exceeded projections at $15.72 million.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY - Free Report) - Analysts at Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of ARS Pharmaceuticals in a research note issued to investors on Thursday, August 14th. Cantor Fitzgerald analyst J. Schimmer now forecasts that the company will post earnings per share of ($1.92) for the year, down from their previous estimate of ($1.44). The consensus estimate for ARS Pharmaceuticals' current full-year earnings is ($0.55) per share. Cantor Fitzgerald also issued estimates for ARS Pharmaceuticals' FY2026 earnings at ($1.01) EPS.

ARS Pharmaceuticals (NASDAQ:SPRY - Get Free Report) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.05). The business had revenue of $15.72 million during the quarter, compared to the consensus estimate of $12.92 million. ARS Pharmaceuticals had a negative return on equity of 21.85% and a negative net margin of 42.74%.

Separately, Wall Street Zen lowered shares of ARS Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating and five have assigned a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and an average price target of $31.00.

ARS Pharmaceuticals Stock Performance

SPRY traded down $1.37 on Monday, hitting $13.50. The company's stock had a trading volume of 3,133,139 shares, compared to its average volume of 1,802,729. The company's 50 day simple moving average is $16.80 and its 200-day simple moving average is $14.35. The firm has a market cap of $1.33 billion, a P/E ratio of -27.55 and a beta of 0.90. ARS Pharmaceuticals has a 12 month low of $10.00 and a 12 month high of $18.90. The company has a quick ratio of 5.98, a current ratio of 6.17 and a debt-to-equity ratio of 0.37.

Institutional Investors Weigh In On ARS Pharmaceuticals

Several hedge funds have recently bought and sold shares of SPRY. Adage Capital Partners GP L.L.C. bought a new stake in ARS Pharmaceuticals during the second quarter valued at approximately $30,154,000. MPM Bioimpact LLC bought a new stake in ARS Pharmaceuticals during the first quarter valued at approximately $16,519,000. Alyeska Investment Group L.P. lifted its position in ARS Pharmaceuticals by 903.0% during the fourth quarter. Alyeska Investment Group L.P. now owns 1,253,724 shares of the company's stock valued at $13,227,000 after purchasing an additional 1,128,724 shares during the last quarter. Cormorant Asset Management LP lifted its position in ARS Pharmaceuticals by 220.0% during the first quarter. Cormorant Asset Management LP now owns 1,600,000 shares of the company's stock valued at $20,128,000 after purchasing an additional 1,100,000 shares during the last quarter. Finally, Aberdeen Group plc bought a new stake in ARS Pharmaceuticals during the first quarter valued at approximately $12,613,000. 68.16% of the stock is currently owned by institutional investors.

Insider Buying and Selling at ARS Pharmaceuticals

In related news, insider Sarina Tanimoto sold 37,656 shares of the company's stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $14.09, for a total transaction of $530,573.04. Following the sale, the insider owned 1,247,447 shares of the company's stock, valued at approximately $17,576,528.23. This represents a 2.93% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, major shareholder James E. Flynn sold 740,149 shares of ARS Pharmaceuticals stock in a transaction that occurred on Friday, June 27th. The shares were sold at an average price of $18.46, for a total transaction of $13,663,150.54. Following the sale, the insider owned 4,887,254 shares of the company's stock, valued at approximately $90,218,708.84. The trade was a 13.15% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 882,649 shares of company stock worth $15,773,760 in the last ninety days. Insiders own 33.50% of the company's stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers.